The predictive value of schema modes on cognitive behavioral therapy outcome for patients with anxiety disorders

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21441

Enrollment

Registered

2020-01-17

Start date

2020-01-17

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorder: either an obsessive compulsive disorder, panic disorder and/or agoraphobia, social anxiety disorder or generalized anxiety disorder

Interventions

Treatment as usual: cognitive behavioral therapy (CBT)

Eligibility

Inclusion criteria

Inclusion criteria: - Adults between 18 and 65 years of age - A primary diagnosis of obsessive compulsive disorder, panic disorder and/or agoraphobia, social anxiety disorder or generalized anxiety disorder, assessed with the Mini International Neuropsychiatric Interview (MINI; Overbeek, Schruers, & Griez, 1997, 1999). - The patient is enrolled for CBT at Pro Persona anxiety department (Nijmegen, Arnhem, Ede or Tiel)

Exclusion criteria

Exclusion criteria: - A psychological treatment primarily focused on personality characteristics - Mental disorders that need acute treatment and/or harm the validity of the measurements: a current psychotic episode, substance abuse or mental retardation - An inability to speak and understand Dutch fluently

Design outcomes

Primary

Measure	Time frame
The severity of patients'symtoms and general psychological functioning will be measured by the Outcome Questionnaire-45 (OQ-45; Lambert et al., 1996).	—

Secondary

Measure	Time frame
The severity of disorder specific symptoms. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS; Goodman et al., 1989a) will be used as a clinician rated instrument in the OCD subgroup. Panic disorder with or without agoraphobia symptoms severity will be assessed with the Panic Disorder Severity Scale (PDSS; Shear et al., 1997; de Beurs, 2002). The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987; van Vliet, 1999) will be administered to measure social anxiety symptoms severity in the SAD subgroup. Severity of generalized anxiety disorder symptoms will be measured for the GAD subgroup by the Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 1990).	—

Measure

Time frame

The severity of disorder specific symptoms. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS; Goodman et al., 1989a) will be used as a clinician rated instrument in the OCD subgroup. Panic disorder with or without agoraphobia symptoms severity will be assessed with the Panic Disorder Severity Scale (PDSS; Shear et al., 1997; de Beurs, 2002). The Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987; van Vliet, 1999) will be administered to measure social anxiety symptoms severity in the SAD subgroup. Severity of generalized anxiety disorder symptoms will be measured for the GAD subgroup by the Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 1990).

—

Contacts

Public ContactManon Peeters

Pro Persona

m.peeters01@propersona.nl024-3436510

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)